Quarterly report
Open the filing on sec.gov
Organogenesis Holdings Inc. (ORGO)
Nasdaq: ORGO · Pharmaceutical Preparations · Canton, MA · filing with the SEC since 2015
Grade5.9
◀ Past 5.5● Present 7.0▶ Future 4.8
The companyfiscal 2025, as filed
Revenue$564M+17.0%
Net income$37.0M+4201.0%
Earnings per share$0.15+1600.0%
Operating cash flow-$10.3M-172.6%
Cash$94.3M-30.7%
Debtn/a
Shareholders’ equity$300M+14.2%
Shares, diluted130.2M-1.1%
Return on equity12.3%
The recordfrom its filings
Filings in 202649
Newest filingNov 5 · 10-Q
Annual reportFeb 26, 2026
Quarterly reportNov 5, 2026
Next report due10-K by Mar 16
Insider sales, 12 months$2.6M
Insider buys, 12 months$0.00
Patents granted61
Filer categoryAccelerated filer
Trailing twelve months to Sep 2026Revenue $352MNet income -$135MCash from operations $10.3Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Annual report to shareholders
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.